Pfizer’s investigational therapy inclacumab failed to outperform a placebo in reducing vaso-occlusive crises in SCD patients ...

I’ve shared reflections from three days after my last sickle cell pain crisis, and then again a month later. Now, four months on, I find myself in a completely different place physically, mentally, ...

The FDA has granted regenerative medicine advanced therapy designation to BEAM-101, a one-time, gene-edited cell therapy for severe SCD.

The FDA has granted regenerative medicine advanced therapy designation to BEAM-101, a one-time, gene-edited cell therapy for severe SCD.